Kamel Laribi

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 14

Top Venues

British journal of haematology

Cancer medicine

Hematological oncology

Annals of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Kamel Laribi, Stéphanie Poulain, Lise Willems, Fatiha Merabet, Charles Herbaux, Damien Roosweil, Inès Laribi de Materre, Xavier Roussel, Morgane Nudel, Sabine Tricot, Jehan Dupuis, Ronan LE Calloch, Benoit Bareau, Véronique Leblond
Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO). British journal of haematology (2024)
Kamel Laribi, Stéphanie Poulain, Lise Willems, Fatiha Merabet, Charles Herbaux, Damien Roosweil, Inès Laribi de Materre, Xavier Roussel, Morgane Nudel, Sabine Tricot, Jehan Dupuis, Ronan LE Calloch, Benoit Bareau, Véronique Leblond
Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO). British journal of haematology 204 (6) (2024)
Kamel Laribi, Stéphanie Poulain, Lise Willems, Fatiha Merabet, Charles Herbaux, Damien Roosweil, Inès Laribi de Materre, Xavier Roussel, Morgane Nudel, Sabine Tricot, Jehan Dupuis, Ronan LE Calloch, Benoit Bareau, Véronique Leblond
Long-term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO). British journal of haematology 204 (6) (2024)
Lionel Ades, Nicolas Duployez, Agnes Guerci-Bresler, Kamel Laribi, Pierre Peterlin, Norbert Vey, Sylvain Thepot, Stefan Wickenhauser, Hacene Zerazhi, Aspassia Stamatoullas, Eric Wattel, Christian Recher, Andrea Toma, Sophie Dimicoli-Salazar, Thorsten Braun, Odile Beyne-Rauzy, Jean-Pierre Marolleau, Stéphane Cheze, Sophie Park, Thomas Cluzeau, Stanislas Nimubona, Dominique Bordessoule, Riad Benramdane, Bruno Quesnel, Shanti Amé, Stéphane de Botton, Fathia Chermat, Claude Preudhomme, Sylvie Chevret, Pierre Fenaux
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations. British journal of haematology 198 (3) (2022)
Julien Labreuche, Deborah Assouan, Eric Durot, Cecile Tomowiak, Damien Roos-Weil, Elise Toussaint, Fontanet Bijou, Richard Lemal, Annie Brion, Kamel Laribi, Loic Ysebaert, Alain Duhamel, Pierre Morel, null null
Does early disease progression predict survival after first line-treatment of Waldenström macroglobulinemia? Hematological oncology 40 (3) (2022)
Nadia Younan, Carole Soussain, Sylvain Choquet, Nathalie Cassoux, Valérie Touitou, Anna Schmitt, Olivier Chinot, Lucie Oberic, Gandhi Damaj, Roch Houot, Hervé Ghesquières, Kamel Laribi, Guido Ahle, Luc Taillandier, Jérôme Paillassa, Emmanuel Gyan, Fabrice Jardin, Vincent Delwail, Jean-Pierre Marolleau, Adrian Tempescul, Philippe Agapé, Marie Bourniquel, Fabienne Vacheret, Ibrahim Jdid, Magali Le Garff-Tavernier, Denis Malaise, Agusti Alentorn, Khê Hoang Xuan, Caroline Houillier
Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study. Hematological oncology (2022)
Cécile Tomowiak, Véronique Leblond, Kamel Laribi, Marine Baron, Christian Puppinck, Paulette Gérard, Elodie Courret, Guy Gorochov, Delphine Sterlin, Olivier Tournilhac, Pierre Morel, Florence Cymbalista, Damien Roosweil, null null
Response to vaccination against SARS-CoV-2 in 168 patients with Waldenström macroglobulinaemia: A French Innovative Leukaemia Organization study. British journal of haematology 197 (4) (2022)
Louise Laloi, Natacha Chaumard Billotey, Pierre-Yves Dumas, Franciane Paul, Alban Villate, Célestine Simand, Luc Fornecker, Florent Puisset, Sarah Bertoli, Marion Boissard Simonet, Kamel Laribi, Dyhia Houyou, Alberto Santagostino, Claire Michel, Gabrielle Roth Guepin, Elodie Guerineau, Reza Tabrizi, Mathilde Hunault, Aurélien Giltat, Eléonore Kaphan, Claude Bulabois, Elodie Cartet, Clément Rocher, Florence Lachenal, Stéphane Morisset, Christian Recher, Arnaud Pigneux, Amine Belhabri, Mauricette Michallet, Anne-Sophie Michallet
Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy. Cancer medicine (2022)
Thibault Comont, Mathieu Meunier, Amina Cherait, Clemence Santana, Thomas Cluzeau, Bohrane Slama, Kamel Laribi, Jean-Thomas Giraud, Sophie Dimicoli, Ana Berceanu, Lenaïg Le Clech, Pascale Cony-Makhoul, Berangere Gruson, Jose Torregrosa, Laurence Sanhes, Vincent Jachiet, Marie-Agnes Azerad, Ahmad Al Jijakli, Emmanuel Gyan, Clement Gaudin, Jonathan Broner, Claire Guerveno, Thierry Guillaume, Pr Lionel Ades, Odile Beyne-Rauzy, Pierre Fenaux, null null
Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study. British journal of haematology 194 (2) (2021)
Kamel Laribi, Mohamad Sobh, David Ghez, Alix Baugier de Materre
Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review. Annals of hematology 100 (6) (2021)
Kamel Laribi, Delphine Bolle, Mustafa Alani, Habib Ghnaya, Anne Besançon, Jonathan Farhi, Kayane Mheidly, Nathalie Denizon, Alix Baugier de Materre
Impact of the relative dose intensity on survival of patients with high-risk myelodysplastic syndromes treated with Azacitidine. Cancer medicine 8 (5) (2019)
Morgane Nudel, Fanny Baran-Marszak, Jean-Baptiste Bossard, Romain Dubois, Héloïse Dapvril, Jehan Dupuis, Kamel Laribi, Jacques-Olivier Bay, Cécile Tomowiak, Brigitte Dreyfus, Stéphane Lepretre, Hélène Demarquette, Frédéric Wallyn, Lidwine Wemeau, Mathieu Wemeau, Stéphanie Poulain, Franck Morschhauser, Florence Cymbalista, Charles Herbaux
Characterisation of a new clinical presentation of chronic lymphocytic leukaemia: symptomatic bronchial involvement, a study from the FILO group. British journal of haematology 186 (5) (2019)
Emmanuel Gyan, Anne Sonet, Pauline Brice, Bruno Anglaret, Kamel Laribi, Christophe Fruchart, Hervé Tilly, Carla Araujo, Pierre Soubeyran, Hugo Gonzalez, Nadine Morineau, Emmanuelle Nicolas-Virelizier, Hervé Ghesquières, Bruno Salles, Réda Bouabdallah, Hubert Orfeuvre, Jonathan Fahri, Olivier Couturier, Luc Xerri, Pierre Feugier, null null
Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study. British journal of haematology 183 (1) (2018)
Kamel Laribi, Stéphanie Poulain, Lise Willems, Fatiha Merabet, Ronan Le Calloch, Jean R Eveillard, Charles Herbaux, Damien Roos-Weil, Driss Chaoui, Xavier Roussel, Sabine Tricot, Jehan Dupuis, Caroline Dartigeas, Benoit Bareau, Marie C Bene, Alix Baugier de Materre, Véronique Leblond
Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO). British journal of haematology 186 (1) (2018)

Kamel Laribi.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Kamel Laribi